Analysis of regulatory mechanisms of enhancers in gastric cancer with double minute chromosomes based on bioinformatics

Mengting An, Guanlin Guo, Jie Wu, Wenjing Sun, Xueyuan Jia

doi:10.16288/j.yczz.24-291

[an error occurred while processing this directive]

Hereditas(Beijing) >

2025 , Vol. 47 >Issue 5: 558 - 572

DOI: https://doi.org/10.16288/j.yczz.24-291

Research Article

Analysis of regulatory mechanisms of enhancers in gastric cancer with double minute chromosomes based on bioinformatics

Expand

1. Department of Medical Genetics, School of Bastic Medical Sciences, Harbin Medical University, Harbin 150081, China
2. Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin 150081, China

Received date: 2024-12-17

Revised date: 2025-02-04

Online published: 2025-02-10

Supported by

Natural Science Foundation of Heilongjiang Province of China(JQ2022C004);Joint Guiding Project of Heilongjiang Natural Science Foundation(LH2021H006);HMU Marshal Initiative Funding(HMUMIF-21007)

Fold

Abstract

Gastric cancer (GC) has a high incidence and mortality rate globally. Double minutes (DMs) are extrachromosomal circular chromosomes that carry amplified oncogenes or drug resistance genes, and they are closely associated with tumorigenesis and drug resistance. To investigate the role and regulatory mechanisms of double minutes in the malignant progression of gastric cancer, we utilize bioinformatics methods to analyze genomic copy number variation data from the CCLE cell line database and TCGA solid tumor database. We analyze and summarize the genomic features of tumor samples with double minutes. Based on these features, we classify gastric cancer samples. We use the FANTOM5 database, R package “GenomicRanges”, Bedtools, and MEME SUITE to analyze the functions of the enhancers on double minutes and their regulated target genes in gastric cancer. Next, we apply the CIBERSORT package and the GDSC drug database to analyze immune cell infiltration and drug resistance in gastric cancer samples with and without double minutes from TCGA. The results show that the genome with a copy number greater than 10 and genomic fragments longer than 50 kb play a significant role. The regulatory role of double minutes enhancers affects drug resistance and tumor immunity, with disruptions in the enhancer-transcription factor-target gene regulatory loops also linked to tumor immunity. Furthermore, the target genes regulated by double minutes enhancers not only alter the expression of immune-related genes but also contribute to increased drug resistance to common chemotherapy agents in gastric cancer samples. High expression of drug resistance-related target genes in gastric cancer samples with double minutes is closely associated with poor prognosis. This study provides new insights for the treatment of gastric cancer patients with double minutes.

Key words： double minute chromosomes; enhancer; gastric cancer; tumor immunity; tumor drug resistance; bioinformatics

Cite this article

Mengting An, Guanlin Guo, Jie Wu, Wenjing Sun, Xueyuan Jia . Analysis of regulatory mechanisms of enhancers in gastric cancer with double minute chromosomes based on bioinformatics[J]. Hereditas(Beijing), 2025 , 47(5) : 558 -572 . DOI: 10.16288/j.yczz.24-291

References

[1]	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet, 2020, 396(10251): 635-648.
[3]	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014, 513(7517): 202-209.
[4]	Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin, 2022, 72(1): 7-33.
[5]	Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol, 2018, 15(3): 139-150.
[6]	Klein G, Klein E. Conditioned tumorigenicity of activated oncogenes. Cancer Res, 1986, 46(7): 3211-3224.
[7]	Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet, 2003, 34(4): 369-376.
[8]	Ilić M, Zaalberg IC, Raaijmakers JA, Medema RH. Life of double minutes: generation, maintenance, and elimination. Chromosoma, 2022, 131(3): 107-125.
[9]	Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature, 2017, 543(7643): 122-125.
[10]	Kim H, Nguyen N-P, Turner K, Wu SH, Gujar AD, Luebeck J, Liu JH, Deshpande V, Rajkumar U, Namburi S, Amin SB, Yi E, Menghi F, Schulte JH, Henssen AG, Chang HY, Beck CR, Mischel PS, Bafna V, Verhaak RGW. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet, 2020, 52(9): 891-897.
[11]	Morton AR, Dogan-Artun N, Faber ZJ, MacLeod G, Bartels CF, Piazza MS, Allan KC, Mack SC, Wang XX, Gimple RC, Wu QL, Rubin BP, Shetty S, Angers S, Dirks PB, Sallari RC, Lupien M, Rich JN, Scacheri PC. Functional enhancers shape extrachromosomal oncogene amplifications. Cell, 2019, 179(6): 1330-1341.e13.
[12]	Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet, 2011, 12(4): 283-293.
[13]	Liu Q, Li CY. The identification of enhancers and its application in cancer studies. Hereditas(Beijing), 2020, 42(9): 817-831.
	刘倩, 李春燕. 增强子的鉴定及其在肿瘤研究中的应用. 遗传, 2020, 42(9): 817-831.
[14]	Lu B, Zou CY, Yang ML, He YY, He JC, Zhang CX, Chen SY, Yu JM, Liu KY, Cao Q, Zhao W. Pharmacological inhibition of core regulatory circuitry liquid-liquid phase separation suppresses metastasis and chemoresistance in osteosarcoma. Adv Sci (Weinh), 2021, 8(20): e2101895.
[15]	Qi SH, Wang QL, Zhang JY, Liu Q, Li CY. The regulatory mechanisms by enhancers during cancer initiation and progression. Hereditas(Beijing), 2022, 44(4): 275-288.
	漆思晗, 王棨临, 张俊有, 刘倩, 李春燕. 增强子调控癌症发生发展的机制研究. 遗传, 2022, 44(4): 275-288.
[16]	Gupta PB, Fillmore CM, Jiang GZ, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 2011, 146(4): 633-644.
[17]	Zhu YF, Gujar AD, Wong C-H, Tjong H, Ngan CY, Gong L, Chen YA, Kim H, Liu JH, Li MH, Mil-Homens A, Maurya R, Kuhlberg C, Sun FY, Yi E, deCarvalho AC, Ruan YJ, Verhaak RGW, Wei C-L. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell, 2021, 39(5): 694-707.e7.
[18]	Lv HF, He YD, Nie CY, Du F, Chen XB. Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer:a case report and literature review. Front Pharmacol, 2022, 13: 1067557.
[19]	Huang PM, Ji FF, Cheung AHK, Fu KL, Zhou QM, Ding X, Chen DY, Lin YF, Wang LY, Jiao Y, Chu ESH, Kang W, To KF, Yu J, Wong CC. Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell Host Microbe, 2024, 32(8): 1365-1379.e10.
[20]	Deshpande V, Luebeck J, Nguyen NPD, Bakhtiari M, Turner KM, Schwab R, Carter H, Mischel PS, Bafna V. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nat Commun, 2019, 10(1): 392.
[21]	Li QY, Tang HN, Hu FF, Qin CJ. Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells. J Cell Biochem, 2019, 120(3): 3853-3860.
[22]	Song CL, Han Y, Luo H, Qin ZW, Chen ZQ, Liu Y, Lu S, Sun HM, Zhou CZ. HOXA10 induces BCL2 expression, inhibits apoptosis, and promotes cell proliferation in gastric cancer. Cancer Med, 2019, 8(12): 5651-5661.
[23]	Li YM, Shi YK, Zhang XY, Li P, Ma L, Hu PB, Xu L, Dai YH, Xia S, Qiu H. FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(4): 166665.
[24]	Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Corti C, Uliano J, Passaro A, de Marinis F. MET in non-small-cell lung cancer (NSCLC): cross ‘a long and winding road’ looking for a target. Cancers (Basel), 2023, 15(19): 4779.
[25]	Cai HQ, Zhang MJ, Cheng ZJ, Yu J, Yuan Q, Zhang J, Cai Y, Yang LY, Zhang Y, Hao JJ, Wang MR, Wan JH. FKBP10 promotes proliferation of glioma cells via activating AKT-CREB-PCNA axis. J Biomed Sci, 2021, 28(1): 13.
[26]	Mori JO, White J, Elhussin I, Duduyemi BM, Karanam B, Yates C, Wang HH. Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients. Front Oncol, 2022, 12: 928357.

Options

Outlines

〈

〉

www.chinagene.cn
备案号：京ICP备09063187号

模态框（Modal）标题

Abstract

Cite this article

References